|Description||ORM-15341, an androgen receptor antagonist, could have potential effect against prostate cancer and commonly found as an active main metabolite of ODM-201. IC50: 38 nM.|
|Synonyms||UNII-9EPS75QMTL; ORM-15341; 9EPS75QMTL; SCHEMBL1815556; GMBPVBVTPBWIKC-NSHDSACASA-N; CS-5191|
|Solubility||DMSO: ＞ 37 mg/mL|
|Application||ORM-15341 is an androgen receptor antagonist that could have potential effect against prostate cancer and commonly found as an active main metabolite of ODM-201.|
|Shelf Life||As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly|
Enzalutamide is an androgen-receptor (AR) antagonist with IC50 of 36 nM. It inhibits the activity of prostate cancer cell Ars, which over expressed in prostate ...
BMS-564929 is a novel androgen receptor (AR) modulator (Ki= 2.11 nM) which has been advanced to clinical trials for the treatment of age-related functional decl...
RU 58841 is a new non-steroidal antiandrogen which has potential for use in treating androgen-dependent skin disorders such as acne, hirsutism and androgen-depe...
GLPG0492, a selective androgen receptor modulator, could be effective in decreasing muscle loss. The treatment study against Duchenne muscular dystrophy of it h...
Bicalutamide is a non-steroidal androgen receptor (AR) antagonist with IC50 of 0.16 μM.
ORM-15341, an androgen receptor antagonist, could have potential effect against prostate cancer and commonly found as an active main metabolite of ODM-201. IC50...
MI-136, with the potential to treat refractory prostate cancer, inhibits DHT-induced expression of androgen receptor (AR) target genes. In vitro: Treatment with...
GLPG0492 R enantiomer
The R-enantiomer of GLPG0492 which is a selective androgen receptor modulator, could be effective in decreasing muscle loss.
Cyproterone acetate is a synthetic derivative of 17-hydroxyprogesterone, and acts as an androgen receptor antagonist as well as a weak progesterone receptor ago...
ODM-201 is a new-generation, potent and selective androgen receptor (AR) inhibitor which is potential useful for treatment of castration-resistant prostate canc...
BX341, also known as bifluranol, is a new fluorinated bibenzyl anti-androgen and one of a series of bibenzyls designed to present some of the hormonal propertie...
Andarine is a selective non-steroidal androgen receptor (AR) agonist with Ki of 4 nM, tissue-selective for anabolic organs.
MK-0773 is a selective androgen receptor modulator for the prevention and treatment of muscle wasting associated with cancer. It designed to improve muscle func...
AZD-3514 is a potent androgen receptor downregulator with potential anticancer cancer activity. AZD3514 is being evaluated in a Phase I clinical trial in patie...
A steroidal antiandrogen drug
Cortexolone 17 alpha-propionate
Cortexolone 17 alpha-propionate, also called as CB-03-01, belonging to the family of ester derivatives of cortexolone, is a potent and topical and peripherally ...
ARN-509, also known as JNJ-56021927, is an androgen receptor antagonist with potential antineoplastic activity. ARN-509 binds to AR in target tissues thereby p...
LGD-4033, also known as VK5211 and Ligandrol, is an investigational selective androgen receptor modulator (SARM) for treatment of conditions such as muscle wast...
LGD-2226 is a selective androgen receptor modulator used in the treatment of muscle wasting and osteoporosis, shows to have an anabolic effect on muscle and bon...
Flutamide is an antiandrogen drug, with its active metablolite binding at androgen receptor with Ki values of 55 nM, and primarily used to treat prostate cancer...